Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CCND1 | P24385 | 2/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819228 | 0.86 | CDK4 (0.54) | CDK4CCND1CCNA2CDK2CDK1 | |
| SCHEMBL2822611 | 0.78 | KMT2A (0.50) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2823600 | 0.78 | KCNN1 (0.62) | MEN1KMT2ANPC1RAB9AKDR | |
| SCHEMBL226477 | 0.77 | KMT2A (0.57) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3957843 | 0.76 | GRM5 (0.58) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5621970 | 0.75 | CDK2 (0.72) | CDK4CCND1CDK2CDK1NPC1 | |
| SCHEMBL29595637 | 0.75 | KDM4E (0.71) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL254903 | 0.75 | KDM4E (0.71) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20919346 | 0.73 | KMT2A (0.57) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14255745 | 0.73 | KDM4E (0.75) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294810-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AG (DE) | 2011-12-01 | — | — | US | claimed |
| CN-102216286-A | Substituted (pyridyl)-azinylamine derivatives as plant protection agents | BAYER CROPSCIENCE SA | 2011-10-12 | — | — | CN | claimed |
| EP-2356102-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS PLANT PROTECTION AGENTS | Bayer CropScience AG (DE) | 2011-08-17 | — | — | EP | claimed |
| WO-2010055114-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS PLANT PROTECTION AGENTS | BAYER CROPSCIENCE SA (FR) | 2010-05-20 | — | — | WO | claimed |
| US-20110294810-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| CN-102216286-A | Substituted (pyridyl)-azinylamine derivatives as plant protection agents | BAYER CROPSCIENCE SA | 2011-10-12 | — | — | CN | disclosed |
| EP-1742634-B1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-7560464-B2 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | KCNJ2, KCNJ1, KCNJ11 | CDK4 2640/4885CCND1 3781/4885CCNA2 3154/4885 |
| US-20110294810-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS PLANT PROTECTION AGENTS | PRXL2A, AZI2, PIR | CDK4 2063/4885CCND1 929/4885CCNA2 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.